NR1H4 and metabolic dysfunction-associated steatohepatitis: A role for FXR agonism for the treatment of NASH has been demonstrated in clinical trials with obeticholic acid, a synthetically modified variant of the natural bile acid chenodeoxycholic acid16,17; several non-bile-acid FXR agonists are also in clinical development18.